Erik van Werkhoven

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials

Joe Y. Chang, Suresh Senan, Marinus A. Paul et al. · The Lancet Oncology · 2015 · 1.5K citations · Full text

Medicine, Oncology, Radiation Oncology +8

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings et al. · Nature Medicine · 2019 · 889 citations · Full text

Medicine, Immunology, Oncology +17

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Salo Ooft, Fleur Weeber, Krijn K. Dijkstra et al. · Science Translational Medicine · 2019 · 826 citations

Medicine, Oncology, Pharmacology +17

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16